Eris Lifesciences, a pharmaceutical company, agreed to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics, an Indian biopharmaceutical company, for $44m. “This divesture of non-core assets allows Biocon Biologics to unlock value within our Branded Formulations portfolio in India and sharpen focus on our core therapy areas like Diabetes, Oncology and Immunology. We believe that Eris Lifesciences is well positioned to build further on the Dermatology and Nephrology franchise in India. Biocon Biologics remains committed to a successful transition of employees of these business units, our product brands, and customers to ensure continuity for patients,” Shreehas Tambe, Biocon Biologics CEO & Managing Director.